Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$10.7b

Exact Sciences Future Growth

Future criteria checks 3/6

Exact Sciences is forecast to grow earnings and revenue by 72.7% and 9.1% per annum respectively. EPS is expected to grow by 73.1% per annum. Return on equity is forecast to be 6.6% in 3 years.

Key information

72.7%

Earnings growth rate

73.1%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate9.1%
Future return on equity6.6%
Analyst coverage

Good

Last updated16 Dec 2024

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

Nov 10
Why Investors Shouldn't Be Surprised By Exact Sciences Corporation's (NASDAQ:EXAS) 27% Share Price Plunge

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Earnings and Revenue Growth Forecasts

NasdaqCM:EXAS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,4186044557218
12/31/20253,055-7521632523
12/31/20242,740-2197421723
9/30/20242,692-21498233N/A
6/30/20242,612-175-15119N/A
3/31/20242,535-240-20112N/A
12/31/20232,500-20432156N/A
9/30/20232,406-282-24139N/A
6/30/20232,301-432-10873N/A
3/31/20232,200-517-298-88N/A
12/31/20222,084-624-438-224N/A
9/30/20222,005-716-443-300N/A
6/30/20221,938-735-437-300N/A
3/31/20221,852-745-330-199N/A
12/31/20211,767-596-238-102N/A
9/30/20211,760-793-11734N/A
6/30/20211,712-82930156N/A
3/31/20211,546-72019109N/A
12/31/20201,491-82471136N/A
9/30/20201,321-327-890N/A
6/30/20201,131-165-238-111N/A
3/31/20201,062-136-262-87N/A
12/31/2019876-213-284-112N/A
9/30/2019724-216-271-88N/A
6/30/2019623-221-248-62N/A
3/31/2019526-219-250-105N/A
12/31/2018454-175-219-69N/A
9/30/2018399-143-203-69N/A
6/30/2018353-124N/A-70N/A
3/31/2018308-119N/A-77N/A
12/31/2017266-114N/A-72N/A
9/30/2017214-130N/A-98N/A
6/30/2017169-141N/A-118N/A
3/31/2017133-155N/A-121N/A
12/31/201699-167N/A-130N/A
9/30/201679-170N/A-133N/A
6/30/201663-175N/A-145N/A
3/31/201650-169N/A-141N/A
12/31/201539-158N/A-134N/A
9/30/201527-150N/A-135N/A
6/30/201514-139N/A-119N/A
3/31/20156-120N/A-104N/A
12/31/20142-100N/A-81N/A
9/30/20141-80N/A-60N/A
6/30/20142-59N/A-46N/A
3/31/20143-52N/A-40N/A
12/31/20134-47N/A-40N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EXAS is expected to become profitable in the next 3 years.

Revenue vs Market: EXAS's revenue (9.1% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: EXAS's revenue (9.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EXAS's Return on Equity is forecast to be low in 3 years time (6.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 23:14
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exact Sciences Corporation is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Raymond MyersBenchmark Company
Bruce JacksonBenchmark Company